Camp4 Therapeutics (NASDAQ: CAMP) reported quarterly losses of $(0.32) per share which missed the analyst consensus estimate of $(0.29) by 10.34 percent. This is a 48.39 percent increase over losses of $(0.62) per share from the same period last year. The company reported quarterly sales of $1.294 million which beat the analyst consensus estimate of $300.000 thousand by 331.33 percent. This is a 50.82 percent increase over sales of $858.000 thousand the same period last year.